NCT04569747

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE2

Sponsor: Dana-Farber Cancer Institute

Condition: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: large_enrollment_target_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.